Revolution Medicines rises on Q3 beats; maintains 2026 guidance

The Quick Take
Read the full report from the original publisher.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents.
Related
Markets
Martin Marietta anticipates $820M 2027 Lhoist North America EBITDA while updating 2026 adjusted EBITDA midpoint to $2.48B
Markets
Paycom forecasts 2026 revenue of $2.213B-$2.218B with 48.5% adjusted EBITDA margin midpoint
Markets
Viavi sees $0.50-$0.52 EPS and highlights semiconductor test as a $100M-plus opportunity
Local
Analyst Sees Bitcoin Rally Potential Despite Democratic Sweep
Bitcoin could see a relief rally as U.S. midterm election uncertainty clears, with a Democratic sweep largely priced in, an analyst said. He warned that slower…
